Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer.

Abstract

Eisai is developing eribulin mesilate (E-7389), a synthetic macrocyclic ketone analogue of the tubulin inhibitor halichondrin B, for the treatment of a variety of solid tumors that include but are not limited to breast and lung cancer. In this context, eribulin is in phase III clinical trials in breast cancer; however, it has also progressed to phase II for… (More)
DOI: 10.1358/dot.2010.46.9.1519020

Topics

  • Presentations referencing similar topics